ClinicalTrials.gg
CompletedNCT03474055Updated Sep 10, 2018

Study on Liquid Bovine Rotavirus Pentavalent Vaccine (LBRV-PV) to Evaluate Lot-to-Lot Consistency and to Compare Non-Inferiority With ROTASIIL (Lyophilized BRV-PV) in Healthy Infants in India

A Phase 2/3 interventional study of Liquid Rotavirus Vaccine in Rotavirus Gastroenteritis, sponsored by Serum Institute of India Pvt. Ltd.. Completed at 8 sites in India. Open to participants aged 6 Weeks to 8 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-10.

Sponsored by Serum Institute of India Pvt. Ltd. · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2017, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,500
Allocation
Randomized
Ages
6 Weeks to 8 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 12 studies in Gastroenteritis with a site in India — none open to participants now, none under way, none of them phase 3. Gastroenteritis · India.

Started
2017
the only one that year
Phase 2/3
2 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
3 of 12
Serum Institute of India Pvt. Ltd.

Among the 12 studies in Gastroenteritis with a site in India, this one is the only one that started in 2017, is one of 2 in phase 2/3, and was the 12th registered.

Gastroenteritis

237 studies on the registry are indexed under Gastroenteritis; 16 are open to participants now.

Browse Gastroenteritis studies →

Open to participants now

None of the 12 studies in Gastroenteritis with a site in India is open now. The open studies under Gastroenteritis, anywhere →

Who these studies take

Of the 13 Gastroenteritis studies recruiting now, 5 (38%) set no upper age limit and 8 (62%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 6 Weeks to 8 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Gastroenteritis with a site in India as a file.
02

Study summary

This study has been designed to compare the liquid formulation of BRV-PV (LBRV-PV) with the lyophilized formulation (ROTASIIL) by testing the vaccine in infants (three doses administered 4 weeks apart, starting at 6-8 weeks of age) in order to demonstrate the non-inferiority in the induction of specific anti-rotavirus IgA antibodies by these vaccines. The study will also evaluate lot-to-lot consistency in the manufacture of LBRV-PV by demonstrating equivalence in the induction of specific anti-rotavirus IgA antibodies across three production lots.

03

Conditions studied

  • Rotavirus Gastroenteritis

Keywords

  • Liquid rotavirus vaccine
  • LBRV-PV
  • Gastroenteritis
  • Diarrhoea
04

Who can participate

Ages eligible
6 Weeks to 8 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy infants as established by medical history and clinical examination before entering the study.
  2. Age: 6-8 weeks at the time of enrollment.
  3. Parental ability and willingness to provide .
  4. Parent who intends to remain in the area with the child during the study period.

Exclusion criteria

Exclusion Criteria:

  1. Presence of diarrhea or vomiting in the previous 72 hours or on the day of enrollment.
  2. Acute disease at the time of enrollment (temporary exclusion)
  3. Concurrent participation in another clinical trial at any point throughout the entire time frame for this study
  4. History of congenital abdominal disorders, intussusception, or abdominal surgery.
  5. Known or suspected impairment of immunological function based on medical history and physical examination.
  6. History of any neurologic disorders or seizures.
  7. Any medical condition in the parents / infant which, in the judgment of the Investigator, would interfere with or serves as a to protocol adherence or a participant's parents' ability to give .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,500 participants (actual)

Study arms

  • Experimental
    LBRV-PV Lot A

    The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot A).

    Biological: Liquid Rotavirus Vaccine

  • Experimental
    LBRV-PV Lot B

    The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot B).

    Biological: Liquid Rotavirus Vaccine

  • Experimental
    LBRV-PV Lot C

    The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot C).

    Biological: Liquid Rotavirus Vaccine

  • Active comparator
    ROTASIIL

    The study participants in this arm will receive ROTASIIL, the licensed lyophilized rotavirus vaccine in India.

    Biological: Liquid Rotavirus Vaccine

Interventions

  • BiologicalLiquid Rotavirus Vaccine

    Liquid Rotavirus Vaccine and Lyophilized Rotavirus Vaccine

    Also known as: ROTASIIL

06

What researchers measure

Primary outcomes

  1. Immunogenicity of rotavirus vaccine

    Serum anti- rotavirus IgA antibody concentrations expressed as GMCs for the comparison of LBRV-PV vaccine and ROTASIIL

    Time frame: 28 days post dose 3

Secondary outcomes

  1. Immunogenicity Endpoints

    GMCs of serum anti- rotavirus IgA antibody among the LBRV-PV lots at four weeks after the third vaccination.

    Time frame: 28 days post dose 3

  2. Immunogenicity Endpoints

    Proportion of subjects achieving IgA antibody concentration ≥20 U/ml for the comparison of LBRV-PV and ROTASIIL.

    Time frame: 28 days post dose 3

07

Study locations

8 sites
  • Hakeem Abdul Hameed Centenary Hospital
    New Delhi, Delhi, India
  • Centre for Vaccine Studies, Prasanna School of Public Health, Manipal University, Manipal,
    Udupi, Karnataka 576104, India
  • KEM Hospital Research Centre
    Pune, Maharashtra 411028, India
  • Bharati Vidyapeeth Medical College and Hospital, Pune
    Pune, Maharashtra 411043, India
  • Department of community Medicine, Dr Sushila Nayar School of Public Health, Mahatma Gandhi Institute of Medical Sciences, Sewagram
    Wardha, Maharashtra 442102, India
  • Sri Ramachandra Medical Centre, Chennai
    Chennai, Tamil Nadu 600116, India
  • Institute of Child Health, Kolkata
    Kolkata, West Bengal 700017, India
  • Post Graduate Institute of Medical Education and Research, Chandigarh
    Chandigarh, 160012, India
08

References and documents

Publications

  • Kawade A, Babji S, Kamath V, Raut A, Kumar CM, Kundu R, Venkatramanan P, Lalwani SK, Bavdekar A, Juvekar S, Dayma G, Patil R, Kulkarni M, Hegde A, Nayak D, Garg BS, Gupta S, Jategaonkar S, Bedi N, Maliye C, Ganguly N, Uttam KG, Niyogi P, Palkar S, Hanumante N, Goyal N, Arya A, Aslam M, Parulekar V, Dharmadhikari A, Gaikwad D, Zade J, Desai S, Kang G, Kulkarni PS. Immunogenicity and lot-to-lot consistency of a ready to use liquid bovine-human reassortant pentavalent rotavirus vaccine (ROTASIIL - Liquid) in Indian infants. Vaccine. 2019 May 1;37(19):2554-2560. doi: 10.1016/j.vaccine.2019.03.067. Epub 2019 Apr 4. PubMed 30955982 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Jun 2018, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2018
First posted
Mar 22, 2018
StartActual
Oct 30, 2017
Primary completionActual
Jun 25, 2018
CompletionActual
Jun 25, 2018
Last update
Sep 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03474055
Responsible party
Sponsor
First posted
Mar 22, 2018
Start date
Oct 30, 2017
Primary completion
Jun 25, 2018
Completion
Jun 25, 2018
Last update
Sep 10, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion